Rasburicase in Tumor Lysis Syndrome

Program of Rasburicase in the Treatment of Hyperuricemia in Children and Adolescent Patients With or at Risk of Tumor Lysis Syndrome.

The purpose of this study is to determine whether rasburicase is effective and safety in correcting hyperuricemia.

List of inclusion Criteria:

• Acute hyperuricemia patients(uric acid>8.0 mg/dl) before/during chemotherapy for hematologic malignancies.

List of exclusion Criteria:

• Hypersensitivity to uricases or any of the excipients.
• Known history of hemolytic anemia (G6PD deficiency).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.